B. Riley analyst Mayank Mamtani raised the firm’s price target on Journey Medical (DERM) to $12 from $9 and keeps a Buy rating on the shares following a transfer of coverage. The firm expects increased visibility into Emrosi’s early launch performance with the Q2 results in mid-August.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DERM: